[HTML][HTML] Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer

H Imaoka, Y Toiyama, M Okigami, H Yasuda… - Gastric cancer, 2016 - Springer
H Imaoka, Y Toiyama, M Okigami, H Yasuda, S Saigusa, M Ohi, K Tanaka, Y Inoue, Y Mohri…
Gastric cancer, 2016Springer
Background Metastasis is a major cause of death in patients with gastric cancer (GC).
MicroRNAs (miRNAs) relating to the epithelial–mesenchymal transition (EMT) control GC
progression and metastasis. The aim of this study was to evaluate serum EMT-associated
miRNAs for metastatic and prognostic noninvasive biomarkers in GC. Methods In the first
step of this study (preliminary experiments), we selected candidate miRNAs associated with
metastasis by analyzing the expression of the miR-200 family (miR-200a, miR-200b, miR …
Background
Metastasis is a major cause of death in patients with gastric cancer (GC). MicroRNAs (miRNAs) relating to the epithelial–mesenchymal transition (EMT) control GC progression and metastasis. The aim of this study was to evaluate serum EMT-associated miRNAs for metastatic and prognostic noninvasive biomarkers in GC.
Methods
In the first step of this study (preliminary experiments), we selected candidate miRNAs associated with metastasis by analyzing the expression of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and miR-203 in serum samples from stage I (n = 12) and stage IV (n = 12) GC patients. The second phase involved the independent validation of candidate miRNAs in serum specimens from 130 patients with GC and 22 controls.
Results
Based on the preliminary experiments, miR-203 was selected as the candidate serum miRNA that was most closely associated with metastasis. Validation analysis revealed that serum miR-203 levels were significantly lower in stage IV than stage I–III GC patients. Serum miR-203 expression was significantly lower in GC patients with a higher T stage, vessel invasion, and lymph node, peritoneal, and distant metastases. Low expression of serum miR-203 was significantly associated with poor disease-free and overall survival. Multivariate analysis revealed that low serum miR-203 expression was an independent predictive marker for lymph node, peritoneal, and distant metastases and a poor prognosis in patients with GC.
Conclusions
Serum miR-203 has the potential to serve as a noninvasive biomarker for prognosis and to predict metastasis in patients with GC.
Springer